# Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

> **NCT06223958** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ocular Therapeutix, Inc.** · enrollment: 344 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** OTX-TKI (axitinib implant)
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT06223958
- **Lead sponsor:** Ocular Therapeutix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-29
- **Primary completion:** 2026-04-29
- **Final completion:** 2027-09-27
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223958, "Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06223958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*